It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Introduction
To evaluate patient–physician communication and patients’ understanding of treatment goals in rheumatoid arthritis (RA).
Methods
A cross-sectional online survey of patients with RA and physicians treating RA was conducted between 16 and 30 June 2021. Participants were asked to rate the importance of 17 goals on a 6-point Likert scale, and mean scores were compared between patients and physicians by the Wilcoxon rank sum test. Patients’ satisfaction with physician communication and their understanding of treatment goals were also assessed.
Results
The responses of 502 patients and 216 physicians were analyzed. The most common patient age group was 50–59 years (28.5%), and the mean disease duration was 10.3 years. Physicians had a mean of 19.2 years of treatment experience and were treating a mean of 44.3 patients. Among the 17 goals assessed, patients placed significantly more importance on drug tapering or discontinuation as short-term goals (3–6 months) and on performing basic activities of daily living, being able to engage in daily tasks, achieving and maintaining remission, maintaining better laboratory values, and drug tapering or discontinuation as long-term goals (5–10 years; all adjusted p < 0.05). Patient treatment satisfaction was significantly associated with disease activity, a feeling of treatment effectiveness, satisfaction with physician communication, and agreement with physician goals.
Conclusion
Differences exist among patients with RA and physicians treating RA regarding the importance of short- and long-term treatment goals. Good patient–physician communication appears to be important for improving patient satisfaction.
Trial registration
University Hospital Medical Information Network identifier: UMIN000044463.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Keio University School of Medicine, Department of Orthopaedic Surgery, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
2 Chiba University Hospital, Department of Allergy and Clinical Immunology, Chiba, Chiba, Japan (GRID:grid.411321.4) (ISNI:0000 0004 0632 2959)
3 Osaka City General Hospital, Department of Orthopaedic Surgery, Osaka, Japan (GRID:grid.416948.6) (ISNI:0000 0004 1764 9308)
4 Seirei Hamamatsu General Hospital, Department of Rheumatology, Hamamatsu, Japan (GRID:grid.415466.4) (ISNI:0000 0004 0377 8408)
5 Eisai Co., Ltd., Tokyo, Japan (GRID:grid.418765.9) (ISNI:0000 0004 1756 5390)
6 Medilead, Inc., Tokyo, Japan (GRID:grid.418765.9)
7 Kyorin University School of Medicine, Department of Nephrology and Rheumatology, Tokyo, Japan (GRID:grid.411205.3) (ISNI:0000 0000 9340 2869)